Atovaquone-proguanil remains a potential stopgap therapy for multidrug-resistant Plasmodium falciparum in areas along the Thai-cambodian border

David L. Saunders*, Suwanna Chaorattanakawee, Panita Gosi, Charlotte Lanteri, Sok Somethy, Worachet Kuntawunginn, Mali Ittiverakul, Soklyda Chann, Carrie Gregory, Char Meng Chuor, Satharath Prom, Michele D. Spring, Chanthap Lon

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

Our recent report of dihydroartemisinin-piperaquine failure to treat Plasmodium falciparum infections in Cambodia adds new urgency to the search for alternative treatments. Despite dihydroartemisinin-piperaquine failure, and higher piperaquine 50% inhibitory concentrations (IC50s) following reanalysis than those previously reported, P. falciparum remained sensitive to atovaquone (ATQ) in vitro. There were no point mutations in the P. falciparum cytochrome b ATQ resistance gene. Mefloquine, artemisinin, chloroquine, and quinine IC50s remained comparable to those from other recent reports. Atovaquone-proguanil may be a useful stopgap but remains susceptible to developing resistance when used as blood-stage therapy.

Original languageEnglish
Pages (from-to)1896-1898
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Volume60
Issue number3
DOIs
StatePublished - Mar 2016
Externally publishedYes

Fingerprint

Dive into the research topics of 'Atovaquone-proguanil remains a potential stopgap therapy for multidrug-resistant Plasmodium falciparum in areas along the Thai-cambodian border'. Together they form a unique fingerprint.

Cite this